Target species
Cattle (beef and dairy cattle)
Indications for use, specifying the target species
Indicated for the treatment and prevention of the following parasites.
Gastrointestinal Roundworms (adults and fourth stage larvae):
Ostertagia spp., Ostertagia lyrata (adult), Ostertagia ostertagi (including inhibited O. ostertagi), Cooperia spp. (including inhibited Cooperia spp), Cooperia oncophora, Cooperia pectinata, Cooperia punctata, Cooperia surnabada, Haemonchus placei, Trichostrongylus spp., Trichostrongylus axei, Trichostrongylus colubriformis, Bunostomum phlebotomum, Nematodirus helvetianus, Oesophagostomum spp. (adult), Oesophagostomum radiatum, Trichuris spp (adult).
Lungworms (adults and fourth stage larvae):
Dictyocaulus viviparus
Warbles (parasitic stages):
Hypoderma bovis, H. lineatum
Mange Mites:
Chorioptes bovis, Sarcoptes scabiei var bovis
Lice:
Damalinia (Bovicola) bovis (biting lice), Linognathus vituli (sucking lice), Haematopinus eurysternus (sucking lice), Solenopotes capillatus (sucking lice).
Horn Flies:
Haematobia irritans.
Prolonged Activity
Applied as recommended, the product prevents reinfections with:
Parasite *
Prolonged Activity
Dictyocaulus viviparus
up to 28 days
Ostertagia spp
up to 28 days
Oesophagostomum radiatum
up to 28 days
Cooperia spp
up to 21 days
Trichostrongylus spp
up to 21 days
Haemonchus placei
up to 14 days
Nematodirus helvetianus
up to 14 days
*The following parasite species are included within each of the relevant genera: Ostertagia ostertagi, O. lyrata, Cooperia oncophora, C. punctata, C. surnabada, Trichostronglus axei, T. colubroformis.
Contraindications
This product is formulated only for topical application to beef and dairy cattle, including lactating dairy cattle. Do not use in other animal species. Do not administer orally or by injection.
Do not use in cases of hypersensitivity to the active substance(s) or to any of the excipient(s).
Special Warnings for each target species
If there is a risk for re-infestation, the advice of a veterinarian should besought regarding the need for and frequency of repeat administration.
Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:
•Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
•Underdosing, which may be due to underestimation of bodyweight, misadministration of the product, or lack of calibration of the dosing device (if any).
Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.
To date no resistance to eprinomectin (a macrocyclic lactone) has been reported within the EU. However resistance to other macrocyclic lactones has been reported in parasite species in cattle within the EU. Therefore, use of this product should be based on local (regional, farm) epidemiological information about susceptibility of nematodes and recommendations on how to limit further selection for resistance to anthelmintics.
While mite and louse numbers decline rapidly following treatment, due to the feeding habits of the parasites, in some cases several weeks may be required for complete eradication.
For effective use, the product should not be applied to areas of the backline covered with mud or manure.
For the best results the product should be part of a program to control both internal and external parasites of cattle based on the epidemiology of these parasites.
Special precautions for use
Special precautions for use in animals
Not to be used in other species; avermectins can cause fatalities in dogs, especially Collies, Old English Sheepdogs and related breeds and crosses, and also in turtles/tortoises.The product should be applied only to healthy skin.
To avoid secondary reactions due to the death of Hypoderma larvae in the oesophagus or in the spine, it is recommended to administer the product at the end of warble fly activity and before the larvae reach their resting sites.
Rainfall at any time before or after treatment will not affect the efficacy of the product.
Special precautions to be taken by the person administering the veterinary medicinal product to animals.
This product may be irritating to human skin and eyes and may cause hypersensitivity.
Avoid skin and eye contact with the product during treatment and when handling recently treated animals.
Users should wear rubber gloves, boots and a waterproof coat when applying the product.
Should clothing become contaminated, remove as soon as possible and launder before re-use.
If accidental skin contact occurs, wash the affected area immediately with soap and water.
If accidental eye exposure occurs, flush eyes immediately with water.
This product may be toxic after accidental ingestion.
Avoid accidental ingestion of the product by hand to mouth contact.
Do not smoke, eat or drink while handling the product.
In the event of ingestion, wash out mouth with water and seek medical advice.
Wash hands after use.
This product is flammable. Keep away from sources of ignition.
Inhalation of the product may cause irritation.
Use only in well ventilated areas or outdoors.
Other precautions
Eprinomectin is very toxic to dung fauna and aquatic organisms and may accumulate in sediments.
The risk to aquatic ecosystems and dung fauna can be reduced by avoiding too frequent and repeated use of eprinomectin (and products of the same anthelmintic class) in cattle.
The risk to aquatic ecosystems will be further reduced by keeping treated cattle away from water bodies for two to four weeks after treatment.
Adverse reactions (frequency and seriousness)
In very rare cases application site reactions (i.e. alopecia) have been reported after the use of the veterinary medicinal product.
The frequency of adverse reactions is defined using the following convention:
•very common (more than 1 in 10 animals treated displaying adverse reaction(s))
•common (more than 1 but less than 10 animals in 100 animals treated)
•uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
•rare (more than 1 but less than 10 animals in 10,000 animals treated)
•very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Use during pregnancy, lactation or lay
May be used in dairy cattle during all stages of lactation.
Studies conducted at three times the recommended use level of 0.5 mg eprinomectin/kg b.w. had no adverse effect on breeding performance of cows or bulls.
Interaction with other medicinal products and other forms of interaction
Since eprinomectin binds strongly to plasma proteins, this should be taken into account if it is used in association with other molecules having the same characteristics.
Amounts to be administered and administration route
Administer only by topical application at the dose rate of 1 ml per 10 kg of body weight, corresponding to the recommended dose rate of 0.5 mg eprinomectin per kg b.w. The product should be applied topically by pouring along the backline in a narrow strip extending from the withers to the tailhead.
To ensure administration of a correct dose, bodyweight should be determined as accurately as possible; accuracy of the dosing device (dosing cup or dosing gun delivery system) should be checked.
For external use. Pour-on use"
All the animals belonging to the same group should be treated at the same time.
Overdose (symptoms, emergency procedures, antidotes), if necessary
In adult cattle, after administration of 5 times the recommended dose (2.5 mg eprinomectin/kg body weight), mild hair loss was observed. No other signs of toxicity were seen.
No antidote has been identified.
Withdrawal period(s)
Meat & offal: 10 days
Milk: zero hours.
Pharmacological particulars
Pharmacotherapeutic group: endectocides, macrocyclic lactones, avermectins.
ATC Vet Code: QP54AA04
Pharmacodynamic properties
Mode of action
Eprinomectin is a member of the macrocyclic lactone class of endectocides. Compounds of the class bind selectively and with high affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve or muscle cells. This leads to an increase in the permeability of the cell membrane to chloride ions with hyperpolarization of the nerve or muscle cell, resulting in paralysis and death of the parasite.
Compounds of this class may also interact with other ligand-gated chloride channels, such as those gated by the neurotransmitter gamma-aminobutyric acid (GABA).
The margin of safety for compounds of this class is attributable to the fact that mammals do not have glutamate-gated chloride channels; the macrocyclic lactones have a low affinity for other mammalian ligand-gated chloride channels, and they do not readily cross the blood-brain barrier.
Pharmacokinetic properties
The bioavailability of topically applied eprinomectin in cattle is about 30% with most absorption occurring by about 10 days after treatment. Eprinomectin is not extensively metabolized in cattle following topical administration. In all biological matrices, the B1a component of eprinomectin is the single most abundant residue.
Eprinomectin consists of the components B1a (= 90%) and B1b (= 10%) which differ by a methylene unit and is not extensively metabolized in cattle. Metabolites amount to approximately 10% of the total residues in plasma, milk, edible tissues and faeces.
The metabolism profile is nearly identical, qualitatively and quantitatively, in the above biological matrices and does not change significantly with time after administration of eprinomectin. The percent contribution of B1a and B1b to the overall metabolite profile remains constant. The ratio of the two drug components in the biological matrices is identical to that in the formulation demonstrating that the two eprinomectin components are metabolized with nearly equal rate constants. Since the metabolism and the tissue distribution of the two components are quite similar, the pharmacokinetics of the two components would be also similar.
Eprinomectin is strongly linked to plasma proteins (99%). Faeces is the major route of elimination.
Environmental properties
Like other macrocyclic lactones, eprinomectin has the potential to adversely affect non-target organisms. Following treatment, excretion of potentially toxic levels of eprinomectin may take place over a period of several weeks. Faeces containing eprinomectin excreted onto pasture by treated animals may reduce the abundance of dung feeding organisms which may impact on the dung degradation.
Eprinomectin is very toxic to aquatic organisms and may accumulate in sediments.
Pharmaceutical particulars
List of excipients
Butylated Hydroxytoluene (E321)
Cetearyl Ethylhexanoate and Isopropyl Myristate
Propylene Glycol Dicaprylocaprate
Denatonium Benzoate
Isopropyl Alcohol
Major Incompatibilities
None known.
Shelf life
Shelf-life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf-life after first opening the immediate packaging: 3 months
Special precautions for storage
Do not store above 30°C. Keep container in the outer carton. Protect from light.
Nature and composition of immediate packaging
Translucent 250 mL and 1L HDPE containers with integral squeeze measure pour system and white HDPE screw caps.
White 1L, 2.5L and 5L HDPE backpacks and white polypropylene screw caps.
Not all packs sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Extremely dangerous to fish and aquatic life. Do not contaminate ponds, waterways or ditches with the product or empty container.
Marketing Authorisation Holder (if different from distributor).
Cattle (beef and dairy cattle)
Indications for use, specifying the target species
Indicated for the treatment and prevention of the following parasites.
Gastrointestinal Roundworms (adults and fourth stage larvae):
Ostertagia spp., Ostertagia lyrata (adult), Ostertagia ostertagi (including inhibited O. ostertagi), Cooperia spp. (including inhibited Cooperia spp), Cooperia oncophora, Cooperia pectinata, Cooperia punctata, Cooperia surnabada, Haemonchus placei, Trichostrongylus spp., Trichostrongylus axei, Trichostrongylus colubriformis, Bunostomum phlebotomum, Nematodirus helvetianus, Oesophagostomum spp. (adult), Oesophagostomum radiatum, Trichuris spp (adult).
Lungworms (adults and fourth stage larvae):
Dictyocaulus viviparus
Warbles (parasitic stages):
Hypoderma bovis, H. lineatum
Mange Mites:
Chorioptes bovis, Sarcoptes scabiei var bovis
Lice:
Damalinia (Bovicola) bovis (biting lice), Linognathus vituli (sucking lice), Haematopinus eurysternus (sucking lice), Solenopotes capillatus (sucking lice).
Horn Flies:
Haematobia irritans.
Prolonged Activity
Applied as recommended, the product prevents reinfections with:
Parasite *
Prolonged Activity
Dictyocaulus viviparus
up to 28 days
Ostertagia spp
up to 28 days
Oesophagostomum radiatum
up to 28 days
Cooperia spp
up to 21 days
Trichostrongylus spp
up to 21 days
Haemonchus placei
up to 14 days
Nematodirus helvetianus
up to 14 days
*The following parasite species are included within each of the relevant genera: Ostertagia ostertagi, O. lyrata, Cooperia oncophora, C. punctata, C. surnabada, Trichostronglus axei, T. colubroformis.
Contraindications
This product is formulated only for topical application to beef and dairy cattle, including lactating dairy cattle. Do not use in other animal species. Do not administer orally or by injection.
Do not use in cases of hypersensitivity to the active substance(s) or to any of the excipient(s).
Special Warnings for each target species
If there is a risk for re-infestation, the advice of a veterinarian should besought regarding the need for and frequency of repeat administration.
Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:
•Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
•Underdosing, which may be due to underestimation of bodyweight, misadministration of the product, or lack of calibration of the dosing device (if any).
Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.
To date no resistance to eprinomectin (a macrocyclic lactone) has been reported within the EU. However resistance to other macrocyclic lactones has been reported in parasite species in cattle within the EU. Therefore, use of this product should be based on local (regional, farm) epidemiological information about susceptibility of nematodes and recommendations on how to limit further selection for resistance to anthelmintics.
While mite and louse numbers decline rapidly following treatment, due to the feeding habits of the parasites, in some cases several weeks may be required for complete eradication.
For effective use, the product should not be applied to areas of the backline covered with mud or manure.
For the best results the product should be part of a program to control both internal and external parasites of cattle based on the epidemiology of these parasites.
Special precautions for use
Special precautions for use in animals
Not to be used in other species; avermectins can cause fatalities in dogs, especially Collies, Old English Sheepdogs and related breeds and crosses, and also in turtles/tortoises.The product should be applied only to healthy skin.
To avoid secondary reactions due to the death of Hypoderma larvae in the oesophagus or in the spine, it is recommended to administer the product at the end of warble fly activity and before the larvae reach their resting sites.
Rainfall at any time before or after treatment will not affect the efficacy of the product.
Special precautions to be taken by the person administering the veterinary medicinal product to animals.
This product may be irritating to human skin and eyes and may cause hypersensitivity.
Avoid skin and eye contact with the product during treatment and when handling recently treated animals.
Users should wear rubber gloves, boots and a waterproof coat when applying the product.
Should clothing become contaminated, remove as soon as possible and launder before re-use.
If accidental skin contact occurs, wash the affected area immediately with soap and water.
If accidental eye exposure occurs, flush eyes immediately with water.
This product may be toxic after accidental ingestion.
Avoid accidental ingestion of the product by hand to mouth contact.
Do not smoke, eat or drink while handling the product.
In the event of ingestion, wash out mouth with water and seek medical advice.
Wash hands after use.
This product is flammable. Keep away from sources of ignition.
Inhalation of the product may cause irritation.
Use only in well ventilated areas or outdoors.
Other precautions
Eprinomectin is very toxic to dung fauna and aquatic organisms and may accumulate in sediments.
The risk to aquatic ecosystems and dung fauna can be reduced by avoiding too frequent and repeated use of eprinomectin (and products of the same anthelmintic class) in cattle.
The risk to aquatic ecosystems will be further reduced by keeping treated cattle away from water bodies for two to four weeks after treatment.
Adverse reactions (frequency and seriousness)
In very rare cases application site reactions (i.e. alopecia) have been reported after the use of the veterinary medicinal product.
The frequency of adverse reactions is defined using the following convention:
•very common (more than 1 in 10 animals treated displaying adverse reaction(s))
•common (more than 1 but less than 10 animals in 100 animals treated)
•uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
•rare (more than 1 but less than 10 animals in 10,000 animals treated)
•very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Use during pregnancy, lactation or lay
May be used in dairy cattle during all stages of lactation.
Studies conducted at three times the recommended use level of 0.5 mg eprinomectin/kg b.w. had no adverse effect on breeding performance of cows or bulls.
Interaction with other medicinal products and other forms of interaction
Since eprinomectin binds strongly to plasma proteins, this should be taken into account if it is used in association with other molecules having the same characteristics.
Amounts to be administered and administration route
Administer only by topical application at the dose rate of 1 ml per 10 kg of body weight, corresponding to the recommended dose rate of 0.5 mg eprinomectin per kg b.w. The product should be applied topically by pouring along the backline in a narrow strip extending from the withers to the tailhead.
To ensure administration of a correct dose, bodyweight should be determined as accurately as possible; accuracy of the dosing device (dosing cup or dosing gun delivery system) should be checked.
For external use. Pour-on use"
All the animals belonging to the same group should be treated at the same time.
Overdose (symptoms, emergency procedures, antidotes), if necessary
In adult cattle, after administration of 5 times the recommended dose (2.5 mg eprinomectin/kg body weight), mild hair loss was observed. No other signs of toxicity were seen.
No antidote has been identified.
Withdrawal period(s)
Meat & offal: 10 days
Milk: zero hours.
Pharmacological particulars
Pharmacotherapeutic group: endectocides, macrocyclic lactones, avermectins.
ATC Vet Code: QP54AA04
Pharmacodynamic properties
Mode of action
Eprinomectin is a member of the macrocyclic lactone class of endectocides. Compounds of the class bind selectively and with high affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve or muscle cells. This leads to an increase in the permeability of the cell membrane to chloride ions with hyperpolarization of the nerve or muscle cell, resulting in paralysis and death of the parasite.
Compounds of this class may also interact with other ligand-gated chloride channels, such as those gated by the neurotransmitter gamma-aminobutyric acid (GABA).
The margin of safety for compounds of this class is attributable to the fact that mammals do not have glutamate-gated chloride channels; the macrocyclic lactones have a low affinity for other mammalian ligand-gated chloride channels, and they do not readily cross the blood-brain barrier.
Pharmacokinetic properties
The bioavailability of topically applied eprinomectin in cattle is about 30% with most absorption occurring by about 10 days after treatment. Eprinomectin is not extensively metabolized in cattle following topical administration. In all biological matrices, the B1a component of eprinomectin is the single most abundant residue.
Eprinomectin consists of the components B1a (= 90%) and B1b (= 10%) which differ by a methylene unit and is not extensively metabolized in cattle. Metabolites amount to approximately 10% of the total residues in plasma, milk, edible tissues and faeces.
The metabolism profile is nearly identical, qualitatively and quantitatively, in the above biological matrices and does not change significantly with time after administration of eprinomectin. The percent contribution of B1a and B1b to the overall metabolite profile remains constant. The ratio of the two drug components in the biological matrices is identical to that in the formulation demonstrating that the two eprinomectin components are metabolized with nearly equal rate constants. Since the metabolism and the tissue distribution of the two components are quite similar, the pharmacokinetics of the two components would be also similar.
Eprinomectin is strongly linked to plasma proteins (99%). Faeces is the major route of elimination.
Environmental properties
Like other macrocyclic lactones, eprinomectin has the potential to adversely affect non-target organisms. Following treatment, excretion of potentially toxic levels of eprinomectin may take place over a period of several weeks. Faeces containing eprinomectin excreted onto pasture by treated animals may reduce the abundance of dung feeding organisms which may impact on the dung degradation.
Eprinomectin is very toxic to aquatic organisms and may accumulate in sediments.
Pharmaceutical particulars
List of excipients
Butylated Hydroxytoluene (E321)
Cetearyl Ethylhexanoate and Isopropyl Myristate
Propylene Glycol Dicaprylocaprate
Denatonium Benzoate
Isopropyl Alcohol
Major Incompatibilities
None known.
Shelf life
Shelf-life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf-life after first opening the immediate packaging: 3 months
Special precautions for storage
Do not store above 30°C. Keep container in the outer carton. Protect from light.
Nature and composition of immediate packaging
Translucent 250 mL and 1L HDPE containers with integral squeeze measure pour system and white HDPE screw caps.
White 1L, 2.5L and 5L HDPE backpacks and white polypropylene screw caps.
Not all packs sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Extremely dangerous to fish and aquatic life. Do not contaminate ponds, waterways or ditches with the product or empty container.
Marketing Authorisation Holder (if different from distributor).
Shipping charges mainland GB zone1
| Value | Weight | Delivery Charge |
| Over £49.00 | Any Weight | FREE |
| Under £49.00 | No weight limit | £4.50 |
| Under £49.00 | Under 250 grams | £3.49 |
Most orders are despatched the same day and standard delivery is 3 to 5 working days from despatch. FAST Expedited options are available at extra cost - these usually arrive in 24-48hrs from dispatch but delays are possible during busy periods.
Postcodes outside of Zone 1 (including some areas within mainland UK) may incur extra carriage charges due to surcharges imposed by the couriers. These will be calculated on the website at the checkout.
NB: Orders placed with faster delivery must be placed before 13:00 to ensure same day dispatch (excluding weekends and bank holidays). Please also check on the product page that the items ordered show 'In Stock' otherwise your order will be delayed until the stock becomes available, which in most cases will only be 24hrs.
Estimated "Usually shipped in" information is shown against most products
Overseas orders
We no longer send goods outside of the UK.
Prescription Items
Prescription items will be sent on receipt of a legally valid signed and dated prescription.
Pick up
We offer a pickup service for orders placed over the phone.
Please ring us on 01833 641112 for more information.
Refrigerated Items
- Refrigerated lines Packaging Cost: Despatched with Woolcool Refrigerated Packaging for £7.50.
Wool cool keeps pharmaceutical products at fridge-like, ambient, or even freezing temperatures for up to 72 hours, and possibly longer depending on the contents and use of ice packs.
Important Delivery Information:
- Receipt Required: Someone must be available to receive the delivery. Woolcool packaging is designed for temperature-controlled goods, so parcels cannot be left unattended.
- Immediate Refrigeration: Upon receipt, refrigerate the contents immediately to ensure your food or medicine remains at the correct temperature.
- Failed Delivery Attempts: We are not responsible for the cost of replacements if a delivery attempt fails due to the absence of someone to receive it.
We want you to be completely satisfied with any purchase. If not any item* can be returned to us within 14 days of receipt for exchange or refund Please give us a ring for a returns number on 01833 641112 or alternatively email sales@hyperdrug.co.uk to obtain a returns number.
*Due to legal requirements medicines may not be returned except to correct an error in despatch or in response to an "official recall". If an item is believed to be faulty it should be returned for inspection and it may be necessary to forward it to the manufacturers for testing before replacements or refunds can be authorised. This does not infringe legal rights. Please contact our customer services for a "Returns Number" which must appear on the outside of the package or it will not be accepted. We advise customers to use an insured method of shipping and to retain proof of despatch. We may refuse returns on products specially obtained or manufactured to order. Items must be returned unsoiled and unused and sent adequately packed and carriage paid.
